PRESENTED AT SOT 2024
Enhancing Drug Safety and ADME Assessment with Organoids
![SOT 2024 Poster](https://resources.huborganoids.nl/hs-fs/hubfs/assets2023/sot-poster-2024.png?width=400&name=sot-poster-2024.png)
Selecting suitable in vivo preclinical drug development models for absorption, distribution, metabolism, excretion (ADME) and toxicology studies poses chall enges due to inter-species variability, limited human relevance, and cost constraints. The FDA Modernization Act 2.0 has endorsed alternative in vitro models, with organoids emerging as valuable tools. Adult stem cell-derived HUB Organoids® from human and preclinical animal tissues have been shown to mimic tissue physiology accurately, offer high-throughput screening, and serve as a robust platform to predict drug toxicity, metabolism, and adverse effects in the intestine.
Download this poster to discover:
- Our innovative ADME and toxicology platform utilizing organoids derived from adult stem cells sourced from both human and animal species, including mini-pig, rat, and dog.
- The practical application of our platform in assessing preclinical gastrointestinal safety.
- Dive into two compelling case studies showcasing the platform's effectiveness in predicting toxicological outcomes.